Publications

Nov 2022

Reduction in surgical site infections by localized administration with D-PLEX100 in patients with multiple risk factors undergoing colorectal surgery

The American Journal of Surgery

Read more >
Sep 2022

D-PLEX, a doxycycline releasing antimicrobial product for surgical site wounds, reduces surgical site infection rates and drug resistant-bacteria in surgical trauma injuries

The 2022 Military Health System Research Symposium (MHSRS)

Read more >
Sep 2022

D-PLEX100, a novel doxycycline formulation that provides high, local concentrations of antibiotic activity for 30 days to reduce surgical site infections

The European Society of Coloproctology (ESCP) 2022 Annual Meeting

Read more >
Sep 2022

A prospective, randomized assessment of a novel, local antibiotic releasing platform for the prevention of superficial and deep surgical site infections

Techniques in Coloproctology

Read more >
Aug 2022

Reduction in Surgical Site Infections by Localized Administration with D-PLEX100 in Patients with Multiple Risk Factors Undergoing Colorectal Surgery

MSA 2022 Annual Meeting

Read more >
Jun 2022

Reduction in local tumor recurrence in a murine R2 resection model comparing locally administered docetaxel-releasing product, OncoPLEX, versus systemic docetaxel

ASCO 2022 Annual Meeting

Read more >
Jun 2022

Incisional microenvironments and reduction in SSIs in patients treated with a local doxycycline-eluting formulation

ASM (American Society for Microbiology) Microbe - Annual Meeting 2022

Read more >
May 2022

From Bench to Bedside: D-PLEX limits AMR occurrence in randomized double-blind phase 2 trial in colorectal surgery patients

13th European and Global CLINAM-Summit

Read more >
Apr 2022

Incisional microenvironments and reduction in SSIs in patients treated with a local doxycycline-eluting formulation

Surgical Infection Society (SIS) - 41st Annual Meeting

Read more >
Mar 2022

D-PLEX100, a novel doxycycline formulation that provides high, local concentrations of antibiotic activity for approximately four weeks to reduce Surgical Site Infections

SAGES 2022 Annual Meeting - The Next Big Thing

Read more >

Technology

PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

Read More >

D-PLEX100

Is designed to prevent the risk of surgical site infections in both bone and soft tissue through its cutting-edge, local, extended-release mechanism

Read More >

D-PLEX1000

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >